JP2018009012A5 - - Google Patents

Download PDF

Info

Publication number
JP2018009012A5
JP2018009012A5 JP2017157335A JP2017157335A JP2018009012A5 JP 2018009012 A5 JP2018009012 A5 JP 2018009012A5 JP 2017157335 A JP2017157335 A JP 2017157335A JP 2017157335 A JP2017157335 A JP 2017157335A JP 2018009012 A5 JP2018009012 A5 JP 2018009012A5
Authority
JP
Japan
Prior art keywords
group
alkyl
divalent
sulfonamide
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017157335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018009012A (ja
JP6496786B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018009012A publication Critical patent/JP2018009012A/ja
Publication of JP2018009012A5 publication Critical patent/JP2018009012A5/ja
Application granted granted Critical
Publication of JP6496786B2 publication Critical patent/JP6496786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017157335A 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用 Active JP6496786B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773773P 2013-03-06 2013-03-06
US61/773,773 2013-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015561536A Division JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019043934A Division JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Publications (3)

Publication Number Publication Date
JP2018009012A JP2018009012A (ja) 2018-01-18
JP2018009012A5 true JP2018009012A5 (enExample) 2019-01-31
JP6496786B2 JP6496786B2 (ja) 2019-04-03

Family

ID=50382628

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157334A Active JP6602351B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157335A Active JP6496786B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015561536A Active JP6196327B2 (ja) 2013-03-06 2014-03-04 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用
JP2017157334A Active JP6602351B2 (ja) 2013-03-06 2017-08-17 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019043934A Active JP6672500B2 (ja) 2013-03-06 2019-03-11 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用

Country Status (20)

Country Link
US (3) US9850264B2 (enExample)
EP (2) EP2964213B1 (enExample)
JP (4) JP6196327B2 (enExample)
KR (2) KR102290134B1 (enExample)
CN (2) CN110279684B (enExample)
AR (1) AR095034A1 (enExample)
AU (3) AU2014225992B2 (enExample)
BR (2) BR122017004254B1 (enExample)
CA (2) CA3133264A1 (enExample)
CL (3) CL2015002485A1 (enExample)
ES (2) ES2835825T3 (enExample)
IL (3) IL241012B (enExample)
MX (2) MX364916B (enExample)
MY (1) MY207109A (enExample)
PH (3) PH12020500285B1 (enExample)
RU (2) RU2663911C2 (enExample)
SG (2) SG10201801471RA (enExample)
TW (1) TWI616200B (enExample)
WO (1) WO2014138037A1 (enExample)
ZA (1) ZA201505134B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518742B (zh) 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
SG11201406629VA (en) * 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CA2871334A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
BR122017004254B1 (pt) 2013-03-06 2021-04-13 Allergan, Inc. Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
WO2015009545A1 (en) * 2013-07-16 2015-01-22 Allergan, Inc. Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
WO2015007830A1 (en) 2013-07-18 2015-01-22 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
CA2948876A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
WO2016149667A1 (en) * 2015-03-19 2016-09-22 University Of Maryland , Baltimore Runx2 transcription factor inhibitors and uses thereof
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CN109715602A (zh) * 2016-03-28 2019-05-03 阿勒根公司 苯基脲衍生物作为n-甲酰肽受体调节剂
EP3442950A1 (en) * 2016-04-12 2019-02-20 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
WO2018066646A1 (ja) 2016-10-06 2018-04-12 第一三共株式会社 尿素誘導体
CN109134533B (zh) * 2017-06-27 2020-08-11 维眸生物科技(上海)有限公司 一种含磷化合物及其制备和应用
CN107814773B (zh) * 2017-11-13 2020-05-22 西安交通大学 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用
RU2712229C2 (ru) * 2018-05-17 2020-01-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
JP2022151437A (ja) * 2021-03-26 2022-10-07 均 石井 網膜炎治療薬。
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CN100497302C (zh) 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
AU2003277575A1 (en) * 2002-11-07 2004-06-07 Takeda Pharmaceutical Company Limited Novel fprl1 ligands and use thereof
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20080008694A1 (en) * 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
JP5502480B2 (ja) * 2006-09-18 2014-05-28 コンピュゲン エルティーディー. 生物活性ペプチド及びその使用方法
EP2242747A1 (de) 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
KR20100101055A (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동 관련 질환의 치료 또는 예방용 약학적 조성물
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2012074785A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
AU2012214265A1 (en) 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2839735A1 (en) 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
EP2731931A1 (en) * 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
CN106518742B (zh) * 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
CA2864893A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
SG11201406629VA (en) 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
BR122017004254B1 (pt) * 2013-03-06 2021-04-13 Allergan, Inc. Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares

Similar Documents

Publication Publication Date Title
JP2018009012A5 (enExample)
JP2017214416A5 (enExample)
JP2017214417A5 (enExample)
JP2017214418A5 (enExample)
JP2017066164A5 (enExample)
JP2011190260A5 (enExample)
JP2015063518A5 (ja) 有機化合物
JP2011207878A5 (enExample)
JP2011213717A5 (enExample)
BR112015005331B8 (pt) Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo
NZ734896A (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
AR103199A1 (es) N-alquilaril-5-oxiaril-octahidrociclopenta[c]pirrol moduladores alóstericos negativos de nr2b
DK2279187T3 (da) Spirocykliske derivater som histondeacetylaseinhibitorer
BR112015032689A2 (pt) composto heterocíclico fundido e uso em controle de pragas do mesmo
DOP2007000014A (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
AR054814A1 (es) Derivados de piridazina
EA201100368A1 (ru) Амидные соединения, полезные в терапии
JP2015512883A5 (enExample)
JP2016529235A5 (enExample)
RU2014107744A (ru) Амидиновое соединение или его соль
JP2019500319A5 (enExample)
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина